Mette Turner, patent attorney at Novo Nordisk, was also present at the hearing
Because GLP-1 drugs are not opioid-based treatments and are not primarily SUD treatments, they are positioned to completely bypass the culture wars surrounding substance use treatment, which will enable them to have a dramatic impact on the global prevalence of addiction, at a scale that existing treatments cannot reach
These are underutilized by psychiatrists but could apply if youre providing nutritional/behavioral counseling
When insulin sensitivity improves, your body can use glucose for energy rather than storing it as fat
Our guest, Zoe Rothblatt, Associate Director of Community Outreach at GHLF, and person living with spondyloarthritis and Crohns disease, joins the conversation to bring her patient perspective